1. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832-6.
2. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733-43.
3. Brenninkmeijer EE, Spuls PI, Legierse CM, et al. Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol. 2008;58:407-14.
4. Jakasa I, de Jongh CM, Verberk MM, et al. Percutaneous penetration of sodium lauryl sulphate is increased in uninvolved skin of patients with atopic dermatitis compared with control subjects. Br J Dermatol. 2006;155:104-9.
5. Jakasa I, Verberk MM, Esposito M, et al. Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol. 2007;127:129-34.
6. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nature Gen. 2006;38:441-6.
7. Bohme M, Soderhall C, Kull I, et al. Filaggrin mutations increase the risk for persistent dry skin and eczema independent of sensitization. J Allergy Clin Immunol. 2012;129:1153-5.
8. Kawasaki H, Nagao K, Kubo A, et al. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. J Allergy Clin Immunol. 2012;129:1538-1546;e1536.
9. Kezic S, O?Regan GM, Lutter R, et al. Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. J Allergy Clin Immunol. 2012;129:1031-9; e1031.
10. Fortugno P, Furio L, Teson M, et al. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis. Hum Mol Genet. 2012;21:4187-4200.
11. De Benedetto A, Rafaels NM, McGirt LY, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127:773-86; e771-7.

12. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120:150-5.
13. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365:1315-27.
14. Paulauskaite I, Eidukaite A, Rudzevičiene O, et al. Investigating the role of Interleukin-33 and Soluble ST2 in pediatric atopic dermatitis. Our Dermatol Online. 2020;11:120-5.
15. Boralevi F, Saint Aroman M, Delarue A, et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. J Eur Acad Dermatol Venereol. 2014;28:1456-62.
16. Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134:818-23.
17. Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344-54.
18. Tang TS, Bieber T, Williams HC. Does ?autoreactivity? play a role in atopic dermatitis? J Allergy Clin Immunol. 2012;129:1209-15; e1202.
19. Ziegler SF, Roan F, Bell BD, et al. The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol. 2013;66:129-55.
20. Wilson SR, The L, Batia LM, et al. The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch. Cell. 2013;155:285-95.
21. Siracusa MC, Saenz SA, Hill DA, et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature. 2011;477:229-33.
22. Lee HJ, Lee NR, Jung M, et al. Atopic March from Atopic Dermatitis to Asthma-Like Lesions in NC/Nga Mice Is Accelerated or Aggravated by Neutralization of Stratum Corneum but Partially Inhibited by Acidification. J Invest Dermatol. 2015;135:3025-33.
23. Garn H, Neves JF, Blumberg RS, et al. Effect of barrier microbes on organ-based inflammation. J Allergy Clin Immunol. 2013;131:1465-78.
24. Wang M, Karlsson C, Olsson C, et al. Reduced diversity in the early fecal microbiota of infants with atopic eczema. J Allergy Clin Immunol. 2008;121:129-34.
25. Forno E, Onderdonk AB, McCracken J, et al. Diversity of the gut microbiota and eczema in early life. Clin Molecular Allergy. 2008;6:11.
26. Bisgaard H, Li N, Bonnelykke K, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol. 2011;128:646-52; e641-645.
27. Abrahamsson TR, Jakobsson HE, Andersson AF, et al. Low diversity of the gut microbiota in infants with atopic eczema. J Allergy Clin Immunol. 2012;129:434-40; 440 e431-2.
28. Penders J, Gerhold K, Stobberingh EE, et al. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood. J Allergy Clin Immunol. 2013;132:601-7; e608.

29. Penders J, Thijs C, van den Brandt PA, et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut. 2007;56:661-7.
30. Ahogo KC, Kouassi YI, Gbery IP, et al. Atopic dermatitis in children: Epidemiological and clinical aspects in Côte d?Ivoire. Our Dermatol Online. 2017;8(Suppl.1):25-7.
31. Sudo N, Sawamura S, Tanaka K, et al. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol. 1997;159:1739-45.
32. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA. 2010;107:11971-5.
33. Naik S, Bouladoux N, Wilhelm C, et al. Compartmentalized control of skin immunity by resident commensals. Science. 2012;337:1115-9.
34. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22:850-9.
35. Hanski I, von Hertzen L, Fyhrquist N, et al. Environmental biodiversity, human microbiota, and allergy are interrelated. Proc Natl Acad Sci U S A. 2012;109:8334-9.
36. Kuo IH, Yoshida T, De Benedetto A, et al. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131:266-78.
37. Stalder JF, Fleury M, Sourisse M, et al. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol. 1994;131:536-40.
38. Miajlovic H, Fallon PG, Irvine AD, et al. Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus. J Allergy Clin Immunol. 2010;126:1184-90; e1183.
39. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, et al. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2011;164:228.
40. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132:1132-8.
41. Binyamin ST, Algamal F, Yamani AN, et al. Prevalence and determinants of eczema among females aged 21 to 32 years in Jeddah city ? Saudi Arabia. Our Dermatol Online. 2017;8:22-6.
42. Strachan DP. Family size, infection and atopy: the first decade of the ?hygiene hypothesis?. Thorax. 2000;55 Suppl 1:S2-10.
43. Xu F, Yan S, Li F, et al. Prevalence of childhood atopic dermatitis: an urban and rural community-based study in Shanghai, China. PLoS One. 2012;7:e36174.
44. Legendre L, Barnetche T, Mazereeuw-Hautier J, et al. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. J Am Acad Dermatol. 2015;72:992-1002.
45. Flohr C, Yeo L. Atopic dermatitis and the hygiene hypothesis revisited. Current problems in dermatology. 2011;41:1-34.

46. Kodama A, Horikawa T, Suzuki T, et al. Effect of stress on atopic dermatitis: investigation in patients after the great hanshin earthquake. J Allergy Clin Immunol. 1999;104:173-6.
47. Sargen MR, Hoffstad O, Margolis DJ. Warm, Humid, and High Sun Exposure Climates Are Associated with Poorly Controlled Eczema: PEER (Pediatric Eczema Elective Registry) Cohort, 2004-2012. J Invest Dermatol. 2014;134:51-7.
48. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006;118:152-69.
49. Bieber T, Cork M, Reitamo S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy. 2012;67:969-75.
50. Al Aboud K, Al Aboud D, Al Aboud A. A vesicating dermatitis from a blister beetle, in the neck of Septuagenarian Saudi male. Our Dermatol Online. 2020;11:95-6.
51. Basex A, Dupre ? A, Christol B. Aspects morphologiques atypiques de l? eczema atopique. Rev Med. 1966;1:62?5.
52. Racouchot MJ. Les petits signes cliniques du terrain eczemateux. Bull Soc Fr Dermatol Syphiligr. 1966;73:531?5.
53. Temime P, Basex A, de Graciansky P. The atypical cutaneous manifestations of atopy. Excerpta Med Int Congr Ser. 1972;251:147?8.
54. Herzberg J. Wenig bekannte Ausdrucksformen der Neurodermitis. Arch Dermatol Forsch. 1972;244:350?2.
55. Malakar S, Ranglani H, Malakar S. Characterizing red dots in atopic dermatitis. Our Dermatol Online. 2021;12:343-4.
56. Pirkl S, Tennstedt D, Egger S, et al. Juvenile plantar dermatosis: wann sind Epikutantestungen indiziert? Hautarzt. 1990;41:22?6.
57. Jones SK, English JSC, Forsyth A, et al. Juvenile plantar dermatosis ? an 8-year follow-up of 102 patients. Clin Exp Dermatol. 1987;12:5?7.
58. Patrizi A, Di Lernia V, Ricci G, et al. Atopic back- ground of a recurrent papular eruption of childhood (frictional lichenoid eruption) Pediatr Dermatol. 1990;7:111?5.
59. Menni S, Piccinno R, Baietta S, et al. Sutton?s summer prurigo: a morphologic variant of atopic dermatitis. Pediatr Dermatol. 1987;4:205?8.
60. Storck H. Neurodermitis disseminata mit Verschlechterung im Sommer, Aufflammen nach Inhalation von Pollenallergenen. Dermatologica. 1960;121:150?1.
61. Kitamura K, Takahashi Y, Sasagawa S. (in Japanese). Jpn J Dermatol. 1950;60:59.
62. Sasagawa S. Studies on the dry form of eczema in childhood patchy pityriasiform lichenoid eczema (Kitamura-Takahashi-Sasagawa). Jpn J Dermatol. 1967;77:62?87.
63. Schmitt J, Langan S, Deckert S, et al. Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation. J Allergy Clin Immunol. 2013;132:1337-47.

64. Barbier N, Paul C, Luger T, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150:96-102.
65. Kreouzi M, Theodorakis N, Prokopiou E, et al. Efficacy and safety of dupilumab in adult moderate-to-severe atopic dermatitis: An update narrative literature review. Our Dermatol Online. 2022;13:6-15.
66. Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants? Dermatitis Quality of Life Index. Br J Dermatol. 2001;144:104-10.
67. Ricci G, Patrizi A, Specchia F, et al. Effect of house dust mite avoidance measures in children with atopic dermatitis. Br J Dermatol. 2000;143:379-84.
68. Kouotou EA, Nansseu JR, Minlo Nyangon EF, et al. Atopic dermatitis in adults from sub-Saharan Africa: epidemiological and clinical patterns, severity, and quality of life. Our Dermatol Online. 2021;12:1-8.
69. Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol. 1999;140:1114-21.
70. Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol. 2003;148:128-33.
71. Hindley D, Galloway G, Murray J, et al. A randomised study of ?wet wraps? versus conventional treatment for atopic eczema. Arch Dis Child. 2006;91:164-8.
72. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931-6.
73. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;165:808-14.
74. Elfatoiki FZ, Mansouri M, Dahbi Skali H, et al. Association atopic dermatitis and psoriasis in Moroccan children. Our Dermatol Online. 2020;11:201-3.
75. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127:808-16.
76. Schmitt J, von Kobyletzki L, Svensson A, et al. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164:415-28.
77. Abramovits W, Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol. 2006;5:236-44.
78. Boguniewicz M, Zeichner JA, Eichenfield LF, et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. J Pediatr. 2008;152:854-9.
79. Huang JT, Rademaker A, Paller AS. Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Arch Dermatol. 2011;147:246-7.

80. Garritsen FM, Brouwer MW, Limpens J, et al. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with the use of GRADE and implications for practice and research. Br J Dermatol. 2014;170:501-13.
81. Proudfoot LE, Powell AM, Ayis S, et al. The European treatment of severe atopic eczema in children taskforce (TREAT) survey. Br J Dermatol. 2013;169:901-9.
82. Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review. J Allergy Clin Immunol. 2014;133:429-38.
83. Bae JM, Choi YY, Park CO, et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132:110-17.
84. Bath-Hextall FJ, Jenkinson C, Humphreys R, et al. Dietary supplements for established atopic eczema. Cochrane Database Syst Rev. 2012;2:CD005205.
85. Gu S, Yang AW, Xue CC, et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev. 2013;9:CD008642.
86. Lopes C, Silva D, Delgado L, et al. Functional textiles for atopic dermatitis: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2013;24:603-13.
87. Flohr C, Nagel G, Weinmayr G, et al. Lack of evidence for a protective effect of prolonged breastfeeding on childhood eczema: lessons from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Two. Br J Dermatol. 2011;165:1280-9.
88. von Berg A, Filipiak-Pittroff B, Kramer U, et al. Allergies in high-risk schoolchildren after early intervention with cow?s milk protein hydrolysates: 10-year results from the German Infant Nutritional Intervention (GINI) study. J Allergy Clin Immunol. 2013;131:1565-73.
89. Pelucchi C, Chatenoud L, Turati F, et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012;23:402-14.
90. Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24:476-86.